

Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: July 23, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-16160 Filed 7-28-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Workshop on Exploring the Science Surrounding the Safe Use of Bioactive Ingredients in Infant Formula: Considerations for an Assessment Framework

**AGENCY:** National Institutes of Health, Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This 2-day, virtual workshop—Exploring the Science Surrounding the Safe Use of Bioactive Ingredients in Infant Formula: Considerations for an Assessment Framework—focuses on the functional state-of-the-science of biologically active human milk components and analogs and the implications for safety assessments when used in infant formula.

**DATES:** The Meeting will be held on September 23–24, 2021, from 10:30 a.m. to 4:30 p.m. (ET).

**ADDRESSES:** This workshop will be videocast at <https://videocast.nih.gov>.

**FOR FURTHER INFORMATION CONTACT:** For information concerning this meeting, contact Dr. Ashley Vargas, Pediatric Growth and Nutrition Branch, Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6701B Rockledge Drive, Room 2423C, Bethesda, MD 20817, telephone: 301-827-6030, email: [ashley.vargas@nih.gov](mailto:ashley.vargas@nih.gov).

**SUPPLEMENTARY INFORMATION:** This **Federal Register** notice is in accordance with 42 U.S.C. 285g, of the Public Health Service Act, as amended. This workshop is led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) Office of Dietary Supplements (ODS), and the Food and Drug Administration (FDA). The workshop is free and open to the public. The workshop will be livestreamed, and the video will be archived. Registration will be available for this meeting at

<https://www.nichd.nih.gov/about/meetings/2021/092321>.

**Alison N. Cernich,**

*Deputy Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.*

[FR Doc. 2021-16118 Filed 7-28-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; IMAT Biospecimen Research.

**Date:** September 30, 2021.

**Time:** 11:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W246, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Jun Fang, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W246, Rockville, Maryland 20850, 240-276-5460, [jfang@mail.nih.gov](mailto:jfang@mail.nih.gov).

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP-2; NCI Clinical and Translational Cancer Research.

**Date:** October 20–21, 2021.

**Time:** 10:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W264, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Ombretta Salvucci, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W264, Rockville, Maryland 20850, 240-276-7286, [salvucco@mail.nih.gov](mailto:salvucco@mail.nih.gov).

**Name of Committee:** National Cancer Institute Initial Review Group; Transition to Independence Study Section (I).

**Date:** October 20–21, 2021.

**Time:** 11:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Delia Tang, M.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850, 240-276-6456, [tangd@mail.nih.gov](mailto:tangd@mail.nih.gov).

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP-3; NCI Clinical and Translational Cancer Research.

**Date:** October 21–22, 2021.

**Time:** 10:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W102, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Shuli Xia, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W102, Rockville, Maryland 20850, [shuli.xia@nih.gov](mailto:shuli.xia@nih.gov).

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP-8; NCI Clinical and Translational Cancer Research.

**Date:** November 4–5, 2021.

**Time:** 10:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W126, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Susan Lynn Spence, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W126, Rockville, Maryland 20850, [susan.spence@nih.gov](mailto:susan.spence@nih.gov).

**Name of Committee:** National Cancer Institute Special Emphasis Panel; SEP-4; NCI Clinical and Translational Cancer Research.

**Date:** November 4–5, 2021.

**Time:** 11:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W254, Rockville, Maryland 20850 (Telephone Conference Call).

**Contact Person:** Eduardo Emilio Chufan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W254, Rockville, Maryland 20850, 240-276-7975, [chufanee@mail.nih.gov](mailto:chufanee@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 26, 2021.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021–16162 Filed 7–28–21; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; P41 NCBIB Review F–SEP.

*Date:* October 25–26, 2021.

*Time:* 09:00 a.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451–3398, [dennis.hlasta@mail.nih.gov](mailto:dennis.hlasta@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, HHS)

Dated: July 23, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021–16161 Filed 7–28–21; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### The National Institutes of Health (NIH) Scientific Workshop on Violence & Related Health Outcomes in Sexual & Gender Minority Communities Open Session

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institutes of Health (NIH) will hold the Phase IV open session for the NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority (SGM) Communities to enhance our understanding of violence against SGM individuals and identify opportunities in violence-related research. The primary objectives of NIH's Phase IV meeting are: (1) To allow the public to participate, and (2) to further refine research opportunities.

**DATES:** The NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities Phase IV virtual meeting will be held on Thursday, August 26, 2021, from 12:00–4:00 p.m. Eastern Daylight Time (New York, GMT).

**ADDRESSES:** The meeting will be held virtually via WebEx.

The preliminary agenda and registration are available at <https://tinyurl.com/SGMwkshp>.

**FOR FURTHER INFORMATION CONTACT:** Irene Avila, Ph.D., Assistant Director, Sexual & Gender Minority Research Office (SGMRO), [avilai@mail.nih.gov](mailto:avilai@mail.nih.gov), 301–594–9701.

#### SUPPLEMENTARY INFORMATION:

*Background:* “Sexual and gender minority” is an umbrella term that includes, but is not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.

In accordance with Section 404N of the 21st Century Cures Act (Pub. L. 114–255), the Director of NIH shall encourage research on SGM populations. The Sexual and Gender Minority Research Office (SGMRO)

coordinates SGM-related research and activities by working directly with NIH Institutes, Centers, and Offices. The Office was officially established in September 2015 within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director and has the following operational goals: (1) Advance rigorous research on the health of SGM populations in both the extramural and intramural research communities; (2) expand SGM health research by fostering partnerships and collaborations with a strategic array of internal and external stakeholders; (3) foster a highly skilled and diverse workforce in SGM health research; and (4) encourage data collection related to SGM populations in research and the biomedical research workforce. The Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities represents an important step in pursuing these goals specifically in the field of violence research.

#### The NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities Phase IV Public Meeting Details

The NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities invites stakeholders throughout the scientific research community, clinical practice communities, patient and family advocates, scientific or professional organizations, federal partners, internal NIH stakeholders, and other interested members of the public to participate and provide comments, questions, or feedback at the workshop. The goal of the meeting is to identify opportunities in violence-related research. Public input will serve as a valuable element in the development of the final proposed research opportunities.

This notice serves as the announcement for the fourth and final phase of the Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities. Phase I was the Request for Information (RFI) <https://www.federalregister.gov/documents/2020/11/25/2020-26094/request-for-information-on-research-opportunities-related-to-the-national-institutes-of-health> published in November 2020. The summary of the comments received can be found on the <https://dpcpsi.nih.gov/sgmro> website. Phase II was a session on the state of the science for violence research affecting SGM communities (a recording will be